Fenofibrate reduces glucose-induced barrier dysfunction in feline enteroids

被引:1
作者
Crawford, Charles K. [1 ]
Beltran, Aeelin [1 ]
Castillo, Diego [1 ]
Matloob, Muhammad S. [1 ]
Uehara, Mimoli E. [1 ]
Quilici, Mary L. [1 ]
Cervantes, Veronica Lopez [1 ]
Kol, Amir [1 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA
关键词
PROTEIN-KINASE-C; INTESTINAL PERMEABILITY; PPAR-ALPHA; DIABETES-MELLITUS; ACTIVATION; PHYSIOLOGY; ORGANOIDS; JUNCTIONS; MANNITOL; CHILDREN;
D O I
10.1038/s41598-023-49874-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Diabetes mellitus (DM) is a common chronic metabolic disease in humans and household cats that is characterized by persistent hyperglycemia. DM is associated with dysfunction of the intestinal barrier. This barrier is comprised of an epithelial monolayer that contains a network of tight junctions that adjoin cells and regulate paracellular movement of water and solutes. The mechanisms driving DM-associated barrier dysfunction are multifaceted, and the direct effects of hyperglycemia on the epithelium are poorly understood. Preliminary data suggest that fenofibrate, An FDA-approved peroxisome proliferator-activated receptor-alpha (PPAR alpha) agonist drug attenuates intestinal barrier dysfunction in dogs with experimentally-induced DM. We investigated the effects of hyperglycemia-like conditions and fenofibrate treatment on epithelial barrier function using feline intestinal organoids. We hypothesized that glucose treatment directly increases barrier permeability and alters tight junction morphology, and that fenofibrate administration can ameliorate these deleterious effects. We show that hyperglycemia-like conditions directly increase intestinal epithelial permeability, which is mitigated by fenofibrate. Moreover, increased permeability is caused by disruption of tight junctions, as evident by increased junctional tortuosity. Finally, we found that increased junctional tortuosity and barrier permeability in hyperglycemic conditions were associated with increased protein kinase C-alpha (PKC alpha) activity, and that fenofibrate treatment restored PKC alpha activity to baseline levels. We conclude that hyperglycemia directly induces barrier dysfunction by disrupting tight junction structure, a process that is mitigated by fenofibrate. We further propose that counteracting modulation of PKC alpha activation by increased intracellular glucose levels and fenofibrate is a key candidate regulatory pathway of tight junction structure and epithelial permeability.
引用
收藏
页数:11
相关论文
共 64 条
  • [21] Diabetic Hyperglycemia Impairs Intestinal Barrier Function in the Setting of Diet-Induced Obesity
    Francis, Kendra L.
    Alonge, Kimberly M.
    Hu, Shannon J. W.
    Phan, Bao Anh N.
    Doan, Tammy P.
    Krutzsch, Cody A.
    Sehat, Renad
    Scarlett, Jarrad M.
    Schwartz, Michael W.
    [J]. DIABETES, 2022, 71
  • [22] OCCLUDIN - A NOVEL INTEGRAL MEMBRANE-PROTEIN LOCALIZING AT TIGHT JUNCTIONS
    FURUSE, M
    HIRASE, T
    ITOH, M
    NAGAFUCHI, A
    YONEMURA, S
    TSUKITA, S
    TSUKITA, S
    [J]. JOURNAL OF CELL BIOLOGY, 1993, 123 (06) : 1777 - 1788
  • [23] Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin
    Furuse, M
    Fujita, K
    Hiiragi, T
    Fujimoto, K
    Tsukita, S
    [J]. JOURNAL OF CELL BIOLOGY, 1998, 141 (07) : 1539 - 1550
  • [24] Managing feline diabetes: current perspectives
    Gottlieb, Susan
    Rand, Jacquie
    [J]. VETERINARY MEDICINE-RESEARCH AND REPORTS, 2018, 9 : 33 - 42
  • [25] The Role of PPAR Alpha in the Modulation of Innate Immunity
    Grabacka, Maja
    Pierzchalska, Malgorzata
    Plonka, Przemyslaw M.
    Pierzchalski, Piotr
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [26] Intestinal barrier function: Molecular regulation and disease pathogenesis
    Groschwitz, Katherine R.
    Hogan, Simon P.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (01) : 3 - 20
  • [27] High-Throughput Screen Identifies Host and Microbiota Regulators of Intestinal Barrier Function
    Grosheva, Inna
    Zheng, Danping
    Levy, Maayan
    Polansky, Omer
    Lichtenstein, Alexandra
    Golani, Ofra
    Dori-Bachash, Mally
    Moresi, Claudia
    Shapiro, Hagit
    Del Mare-Roumani, Sara
    Valdes-Mas, Rafael
    He, Yiming
    Karbi, Hodaya
    Chen, Minhu
    Harmelin, Alon
    Straussman, Ravid
    Yissachar, Nissan
    Elinav, Eran
    Geiger, Benjamin
    [J]. GASTROENTEROLOGY, 2020, 159 (05) : 1807 - 1823
  • [28] Kaufman FR, 2002, J PEDIATR ENDOCR MET, V15, P737
  • [29] Fenofibrate - A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus
    Keating, Gillian M.
    Croom, Katherine F.
    [J]. DRUGS, 2007, 67 (01) : 121 - 153
  • [30] Integrated physiology and systems biology of PPARα
    Kersten, Sander
    [J]. MOLECULAR METABOLISM, 2014, 3 (04): : 354 - 371